Scarica l'app Stockscreener
6.86
5.70%
0.37
Precedente Chiudi:
$6.49
Aprire:
$6.59
Volume 24 ore:
225.27K
Relative Volume:
1.41
Capitalizzazione di mercato:
$146.64M
Reddito:
$66.59M
Utile/perdita netta:
$-104.93M
Rapporto P/E:
-1.3859
EPS:
-4.95
Flusso di cassa netto:
$-96.48M
1 W Prestazione:
-7.42%
1M Prestazione:
+4.57%
6M Prestazione:
+17.06%
1 anno Prestazione:
-44.41%
Intervallo 1D:
$6.54
$7.73
Intervallo di 1 settimana:
$6.45
$7.73
Portata 52W:
$4.09
$13.43
Enanta Pharmaceuticals Inc Stock (ENTA) Company Profile
Nome
Enanta Pharmaceuticals Inc
Settore
Industria
Telefono
617 607 0800
Indirizzo
4 KINGSBURY AVENUE, WATERTOWN, MA
Confronta ENTA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ENTA
Enanta Pharmaceuticals Inc
|
6.86 | 138.73M | 66.59M | -104.93M | -96.48M | -4.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
387.77 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
556.55 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.93 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
637.56 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.10 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Enanta Pharmaceuticals Inc Stock (ENTA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-28 | Ripresa | H.C. Wainwright | Buy |
| 2023-08-09 | Downgrade | JP Morgan | Neutral → Underweight |
| 2023-08-08 | Downgrade | Jefferies | Buy → Hold |
| 2022-12-09 | Iniziato | H.C. Wainwright | Buy |
| 2022-07-06 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2022-06-01 | Aggiornamento | Evercore ISI | Underperform → In-line |
| 2021-10-07 | Iniziato | Jefferies | Buy |
| 2021-09-09 | Iniziato | SVB Leerink | Mkt Perform |
| 2021-01-29 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2020-11-24 | Iniziato | Evercore ISI | Underperform |
| 2020-08-28 | Ripresa | ROTH Capital | Buy |
| 2020-08-26 | Iniziato | Piper Sandler | Overweight |
| 2020-07-27 | Aggiornamento | JMP Securities | Mkt Perform → Mkt Outperform |
| 2020-03-17 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2019-11-22 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-09-26 | Downgrade | JP Morgan | Neutral → Underweight |
| 2019-05-24 | Iniziato | Wolfe Research | Outperform |
| 2019-04-23 | Aggiornamento | Berenberg | Hold → Buy |
| 2018-12-13 | Iniziato | Berenberg | Hold |
| 2018-06-06 | Iniziato | ROTH Capital | Buy |
| 2018-02-08 | Downgrade | JP Morgan | Overweight → Neutral |
| 2018-01-02 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2017-11-21 | Reiterato | RBC Capital Mkts | Outperform |
| 2017-09-15 | Iniziato | RBC Capital Mkts | Outperform |
| 2017-07-11 | Aggiornamento | JMP Securities | Mkt Perform → Mkt Outperform |
| 2016-04-28 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2016-02-09 | Reiterato | Barclays | Underweight |
| 2015-10-23 | Downgrade | Barclays | Equal Weight → Underweight |
| 2015-10-23 | Aggiornamento | JMP Securities | Mkt Perform → Mkt Outperform |
Mostra tutto
Enanta Pharmaceuticals Inc Borsa (ENTA) Ultime notizie
JMP Securities Issues Positive Forecast for Enanta Pharmaceuticals (NASDAQ:ENTA) Stock Price - Defense World
Citizens JMP raises Enanta Pharmaceuticals stock price target to $25 from $24 - Investing.com Canada
Order flow analysis tools used on Enanta Pharmaceuticals Inc.Daily Profit Watch With Forecast Confidence - Newser
Top chart patterns to watch in Enanta Pharmaceuticals Inc.Free Capital Growth With Controlled Risk Picks - Newser
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2025 - BioSpace
Enanta Pharmaceuticals Reports Steady Progress in Q3 2025 - TipRanks
What makes Enanta Pharmaceuticals Inc. stock price move sharplyFree Entry Plan for Oversold Reversal Stocks - Newser
Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Tops Revenue Estimates - sharewise.com
Enanta Pharmaceuticals Sees Narrower Losses And Brighter Analyst Views - Finimize
Enanta Pharmaceuticals: Fiscal Q3 Earnings Snapshot - San Francisco Chronicle
Enanta Pharmaceuticals shares rise 1.85% after-hours following positive RSVHR trial progress and FDA label expansion approval. - AInvest
Enanta Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Enanta Q3 FY22 Revenue Down 17% YoY, Operations Supported by $204.1mln. - AInvest
Detecting price anomalies in Enanta Pharmaceuticals Inc. with AIEquity Portfolio Outlook and Performance Summary - Newser
Leading vs lagging indicators on Enanta Pharmaceuticals Inc. performanceFree Daily Profit Focused Stock Screener - Newser
Will Enanta Pharmaceuticals Inc. price bounce be sustainableRisk-Managed Swing Setup and Signal Analysis - Newser
What technical models suggest about Enanta Pharmaceuticals Inc.’s comebackProfitable Trading Blueprint with Entry Zones - Newser
Is it too late to sell Enanta Pharmaceuticals Inc.Weekly Trend Watch with Market Signals - Newser
How Interest Rate Changes Impact Enanta Pharmaceuticals Inc. Stock PerformanceSummary of Reliable Long-Term Trade Models - Newser
Enanta Pharmaceuticals Inc. recovery potential after sell offSafe Entry Screening with Data Backed Analysis - Newser
Has Enanta Pharmaceuticals Inc. Stock Ever Crashed Historical Volatility ReviewShort-Term Stock Trend Forecast Guide - Newser
Enanta ENTA 2025Q3 Earnings Preview Downside Ahead on Weak Revenue Projections - AInvest
XtalPi and DoveTree Announce Landmark $6 Billion AI Drug Discovery Collaboration - Seeking Alpha
Enanta Pharmaceuticals Inc. Company Revenue and Profit Trends: A Deep DiveFree Trade Setups With Clear Risk Limits - Newser
Enanta Pharmaceuticals to Participate in the H.C. Wainwright & Co. “HCW@Home” Series - BioSpace
Enanta Pharmaceuticals to Participate in H.C. Wainwright & Co.'s Virtual Fireside Chat - AInvest
Can volume confirm reversal in Enanta Pharmaceuticals Inc.Free Consistent Profit Pattern Recognition Tools - Newser
Is Enanta Pharmaceuticals Inc. stock overvalued or undervaluedUnprecedented market success - Jammu Links News
How does Enanta Pharmaceuticals Inc. generate profit in a changing economyAchieve breakthrough gains with expert advice - Jammu Links News
How strong is Enanta Pharmaceuticals Inc. company’s balance sheetDiscover stocks with explosive growth potential - Jammu Links News
How does Enanta Pharmaceuticals Inc. compare to its industry peersAchieve impressive returns with smart timing - Jammu Links News
Is Enanta Pharmaceuticals Inc. a growth stock or a value stockAchieve remarkable returns with smart investing - Jammu Links News
Enanta Pharmaceuticals Inc Azioni (ENTA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.91%
3.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):